TG Therapeutics Inc [TGTX] stock is trading at $35.47, up 1.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TGTX shares have gain 6.29% over the last week, with a monthly amount drifted -4.06%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on October 29, 2024, when TD Cowen initiated its Buy rating and assigned the stock a price target of $50. Previously, Goldman upgraded its rating to Neutral on August 02, 2023, and dropped its price target to $12. BofA Securities started tracking the stock assigning a Underperform rating and suggested a price target of $5 on May 20, 2022. B. Riley Securities reiterated its recommendation of a Buy and reduced its price target to $35 on February 23, 2022. Goldman downgraded its rating to Sell for this stock on November 15, 2021, and downed its price target to $26. In a note dated April 20, 2021, Goldman initiated an Neutral rating and provided a target price of $50 on this stock.
TG Therapeutics Inc [TGTX] stock has fluctuated between $15.16 and $46.48 over the past year. Currently, Wall Street analysts expect the stock to reach $19.8 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $35.47 at the most recent close of the market. An investor can expect a potential drop of -44.18% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 386.39M for the trailing twelve months, which represents a growth of 90.40%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.15%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.1%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.19 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, TG Therapeutics Inc’s Current Ratio is 4.02. In addition, the Quick Ratio stands at 3.04 and the Cash Ratio stands at 0.82. Considering the valuation of this stock, the price to sales ratio is 14.57, the price to book ratio is 23.64 and price to earnings (TTM) ratio is 145.37.
Transactions by insiders
Recent insider trading involved Power Sean A, CFO, that happened on Jan 03 ’25 when 11337.0 shares were sold. CFO, Power Sean A completed a deal on Jan 06 ’25 to sell 10021.0 shares. Meanwhile, Officer Power Sean A bought 10021.0 shares on Jan 06 ’25.
